sever
commerci
assay
avail
detect
nucleic
acid
multipl
respiratori
pathogen
singl
specimen
headtohead
comparison
assay
use
singl
set
standard
specimen
provid
addit
inform
key
assay
paramet
sensit
specif
lower
limit
detect
help
inform
decis
regard
method
use
evalu
two
realtim
pcr
platform
fasttrack
ftd
multiplex
respiratori
panel
taqman
array
card
tac
simultan
uniplex
detect
multipl
respiratori
pathogen
two
set
sampl
use
evalu
assay
one
set
creat
spike
pool
nasal
wash
phosphat
buffer
salin
specifi
volum
known
concentr
viru
andor
bacteria
clinic
nasal
wash
specimen
children
lower
respiratori
tract
ill
compris
set
thirteen
pathogen
target
compar
two
platform
test
valid
panel
spike
sampl
reveal
sensit
ftd
tac
assay
respect
specif
could
reliabl
calcul
due
suspect
contamin
sampl
substrat
interassay
agreement
high
n
target
previous
untest
clinic
specimen
test
assay
reveal
high
percent
agreement
n
except
rhinoviru
enteroviru
streptococcu
pneumonia
limit
evalu
includ
extract
valid
sampl
two
differ
method
evalu
assay
differ
laboratori
howev
neither
factor
significantli
impact
interassay
agreement
set
sampl
demonstr
assay
could
reliabl
detect
clinic
relev
concentr
bacteri
viral
pathogen
tradit
microbiolog
method
continu
play
import
role
determin
caus
respiratori
tract
infect
nucleic
acid
detect
test
diagnost
tool
choic
mani
respiratori
pathogen
advanc
diagnost
offer
sever
advantag
tradit
method
murdoch
et
al
may
adapt
includ
addit
target
need
simultan
detect
multipl
organ
capac
detect
organ
would
otherwis
difficult
identifi
due
fastidi
less
viabl
present
small
amount
quantifi
amount
organ
sampl
measur
pathogen
load
sever
commerci
inhous
assay
avail
detect
multipl
pathogen
limit
publish
studi
headtohead
comparison
sakthivel
et
al
present
evalu
commerci
fasttrack
respiratori
kit
fasttrack
diagnost
luxembourg
realtim
multiplex
pcr
assay
taqman
array
card
tac
formerli
taqman
lowdens
array
tlda
life
technolog
carlsbad
ca
realtim
multipl
uniplex
pcr
platform
produc
nation
center
respiratori
diseas
us
center
diseas
control
prevent
cdc
kodani
et
al
evalu
came
part
assess
diagnost
platform
pneumonia
etiolog
research
child
health
perch
larg
multicent
standard
case
control
studi
etiolog
sever
sever
pneumonia
five
african
two
asian
countri
adegbola
levin
purpos
studi
conduct
head
head
evalu
fasttrack
diagnost
ftd
tac
real
time
pcr
respiratori
pathogen
assay
chose
conduct
initi
evalu
use
standard
valid
panel
sensit
specif
assay
could
readili
compar
gold
standard
case
cultur
inhous
pcr
assay
ultim
goal
evalu
assay
potenti
use
larg
field
base
epidemiolog
studi
also
wish
assess
perform
evalu
true
clinic
specimen
therefor
also
evalu
set
specimen
obtain
children
respiratori
ill
describ
ftd
assay
evalu
includ
viral
bacteri
target
multiplex
six
pool
tabl
rsv
ab
consid
two
target
though
current
commerci
avail
version
ftd
assay
detect
pathogen
ftd
assay
test
specimen
per
run
includ
intern
posit
neg
control
well
extract
control
tac
assay
evalu
compris
uniplex
pcr
assay
conduct
simultan
duplic
singl
microfluid
card
eight
port
one
port
dedic
neg
control
anoth
dedic
posit
control
allow
test
clinic
specimen
per
run
singl
card
two
intern
posit
control
assay
four
nucleic
acid
extract
control
assay
includ
card
kodani
et
al
ftd
platform
requir
nucleic
acid
elut
volum
divid
six
pcr
pool
templat
nucleic
acid
per
pool
tac
platform
requir
per
pcr
reaction
templat
nucleic
acid
ad
port
two
set
sampl
use
evalu
assay
valid
panel
contain
respiratori
pathogen
known
concentr
set
clinic
specimen
undergon
diagnost
assess
fig
sever
ident
aliquot
valid
panel
onlin
supplementari
tabl
construct
use
headtohead
evalu
ftd
tac
assay
sampl
contain
virus
known
quantiti
sampl
known
dilut
sampl
sampl
spike
pool
nasal
wash
healthi
adult
undergon
physic
examin
demonstr
free
respiratori
symptom
otherwis
healthi
assess
physic
examin
screen
laboratori
test
sampl
concentr
confirm
combin
follow
use
turbomet
follow
confirm
coloni
count
plaqu
assay
method
five
sampl
nasal
wash
healthi
adult
spike
virus
serv
neg
control
sampl
part
two
panel
sampl
includ
virus
bacteria
viralbacteri
mixtur
known
quantiti
sampl
dilut
sampl
sampl
spike
phosphat
buffer
salin
pb
addit
five
neg
control
consist
pb
alon
sampl
panel
design
evalu
sensit
assay
within
rang
pathogen
concentr
commonli
found
clinic
specimen
assess
potenti
inhibit
due
matrix
effect
nasal
wash
specimen
panel
design
also
took
consider
limit
detect
previous
publish
tac
kodani
et
al
well
report
fast
track
manufactur
rang
copiesml
averag
limit
detect
copiesml
sampl
contain
combin
pathogen
includ
second
part
panel
simul
mix
infect
total
panel
contain
singl
pathogen
sampl
mix
pathogen
sampl
neg
control
valid
panel
assess
ftd
test
john
hopkin
univers
school
public
health
center
immun
research
cir
laboratori
tac
evalu
perform
cdc
divis
bacteri
diseas
ftd
evalu
total
nucleic
acid
extract
done
nuclisen
minimag
biomerieux
marci
letoil
franc
elut
specimen
final
volum
nucleic
acid
realtim
pcr
perform
use
appli
biosystem
platform
appli
biosystem
foster
citi
ca
cycl
condit
min
min
cycl
follow
tac
evalu
total
nucleic
extract
done
invimag
bacteria
dna
panel
invitek
germani
kingfish
ml
extract
platform
thermo
scientif
waltham
elut
specimen
final
volum
nucleic
acid
realtim
pcr
perform
use
appli
biosystem
ht
realtim
pcr
platform
cycl
condit
min
min
cycl
follow
min
agpathid
onestep
master
mix
enzym
panel
appli
biosystem
foster
citi
ca
use
platform
rt
step
includ
method
assay
perform
evalu
use
set
nasopharyng
wash
specimen
obtain
children
month
age
lower
respiratori
tract
ill
inpati
outpati
unit
state
april
decemb
method
nucleic
acid
extract
clinic
sampl
use
evalu
use
kingfish
method
describ
perform
cdc
divis
bacteri
diseas
half
extract
nucleic
acid
retain
cdc
tac
evalu
rest
sent
john
hopkin
univers
school
public
health
cir
laboratori
test
ftd
analyt
clinic
sampl
posit
ftd
tac
result
manual
analyz
adjust
fluoresc
threshold
target
ftd
standard
ct
cutoff
use
avoid
sensit
calcul
assay
use
valid
panel
concord
method
assess
kappa
statist
use
result
valid
panel
sampl
clinic
specimen
target
imperfect
agreement
mcnemar
test
use
test
independ
overal
platform
exhibit
high
sensit
detect
known
pathogen
valid
panel
run
valid
accord
specif
neg
posit
extract
control
ftd
platform
detect
true
posit
total
possibl
pathogen
tac
detect
true
posit
total
possibl
pathogen
total
adjust
account
avail
differ
target
two
test
ftd
platform
includ
legionella
target
tac
platform
includ
staphylococcu
aureu
parainfluenza
viru
type
coronaviru
coronaviru
target
overal
sensit
ftd
tac
respect
close
align
sensit
report
ftd
overal
sensit
previous
report
tac
kodani
et
al
prill
et
al
weinberg
et
al
platform
detect
valid
sampl
contain
singl
pathogen
n
two
except
tac
unabl
detect
lowest
concentr
influenza
type
tcid
neither
platform
abl
detect
enteroviru
coxsacki
dilut
onlin
supplementari
tabl
platform
abl
detect
least
one
pathogen
includ
mix
valid
sampl
n
onlin
supplementari
tabl
howev
three
mix
sampl
one
pathogen
could
detect
ftd
platform
five
mix
sampl
one
pathogen
could
detect
tac
ftd
platform
unabl
detect
aureu
cfuml
presenc
influenza
type
dilut
unabl
detect
aureu
cfuml
presenc
haemophilu
influenza
type
b
cfuml
rhinoviru
dilut
aureu
h
influenza
type
b
ftd
multiplex
pool
influenza
type
rhinoviru
pool
tac
unabl
detect
rhinoviru
dilut
presenc
streptococcu
pneumonia
cfuml
unabl
detect
pneumonia
cfuml
presenc
either
influenza
type
dilut
adenoviru
dilut
unabl
detect
h
influenza
type
b
cfuml
presenc
pneumonia
cfuml
neither
platform
detect
pneumonia
cfuml
presenc
h
influenza
cfuml
specif
calcul
use
valid
panel
nasal
wash
fluid
use
substrat
sampl
valid
panel
suspect
contain
rhinoviru
pneumonia
aureu
previous
undetect
cultur
rhinoviru
detect
tac
spike
nasal
wash
specimen
ftd
spike
nasal
wash
specimen
nasal
wash
pool
sever
healthi
individu
like
specimen
includ
individu
colon
pneumonia
andor
aureu
asymptomat
shed
rhinoviru
nasal
wash
neg
control
came
differ
pool
rhinoviru
detect
ftd
assay
detect
pneumonia
specimen
insuffici
quantiti
test
two
sampl
target
tac
detect
pneumonia
sampl
aureu
detect
ftd
spike
nasal
wash
sampl
exclud
two
sampl
insuffici
quantiti
test
target
well
three
neg
nasal
wash
control
valid
panel
sampl
creat
spike
pb
instead
nasal
wash
ie
sampl
tac
ftd
detect
one
fals
posit
pneumonia
differ
sampl
ftd
platform
also
detect
fals
posit
parainfluenza
type
result
pneumonia
h
influenza
mix
sampl
posit
tac
result
posit
two
two
well
apart
pneumonia
posit
one
well
posit
result
mean
ct
valu
specimen
posit
one
well
mean
ct
valu
specimen
posit
well
p
b
twelv
valid
panel
sampl
intent
spike
pneumonia
seven
present
quantiti
cfuml
detect
tac
well
remain
sampl
present
quantiti
cfuml
two
detect
singl
tac
well
three
detect
either
well
compar
analysi
consid
target
includ
tac
ftd
platform
tabl
target
nearli
perfect
agreement
individu
percent
agreement
target
greater
kappa
valu
rang
percent
agreement
lower
pneumonia
kappa
valu
mcnemar
test
pair
data
indic
pneumonia
target
differ
detect
two
platform
signific
howev
includ
pb
spike
valid
sampl
percent
agreement
pneumonia
increas
differ
two
platform
longer
signific
among
clinic
specimen
n
total
posit
result
detect
ftd
tac
assay
respect
percent
agreement
high
three
pathogen
target
tabl
three
rhinoviru
enteroviru
pneumonia
rhinoviru
pneumonia
show
statist
signific
differ
tac
detect
rhinoviru
posit
result
wherea
ftd
platform
detect
similarli
tac
detect
posit
pneumonia
result
wherea
ftd
platform
detect
specimen
set
averag
ct
valu
rhinoviru
posit
pneumonia
posit
result
detect
tac
ftd
platform
respect
except
pneumonia
rhinoviru
fewer
specimen
test
posit
pathogen
overal
platform
demonstr
high
sensit
interassay
agreement
detect
pathogen
known
quantiti
set
spike
valid
sampl
tac
shown
elsewher
less
sensit
individu
realtim
pcr
assay
primer
probe
kodani
et
al
perhap
smaller
specimen
volum
tac
well
compar
typic
individu
assay
howev
reduc
sensit
appar
evalu
lowest
concentr
influenza
pathogen
includ
mix
infect
sampl
therefor
reduc
sensit
may
much
clinic
relev
interassay
agreement
moder
pneumonia
target
valid
sampl
taken
consider
may
reflect
differ
assay
design
rhinoviru
pneumonia
aureu
frequent
detect
low
level
first
sampl
like
nasal
wash
pool
healthi
adult
includ
specimen
one
adult
carrier
agent
pathogen
detect
frequent
ftd
assay
tac
sampl
remov
analysi
agreement
two
platform
detect
pneumonia
excel
convers
pneumonia
detect
frequent
tac
set
clinic
specimen
ftd
assay
true
rhinoviru
enteroviru
reduc
sensit
ftd
rhinoviru
speci
primer
particularli
b
c
strain
note
elsewher
sakthivel
et
al
sinc
time
evalu
rhinoviru
primer
fasttrack
platform
rhinoviru
target
tac
platform
updat
target
interassay
agreement
evalu
high
n
similar
result
anoth
headtohead
evalu
includ
ftd
platform
anderson
et
al
evalu
least
two
import
limit
may
affect
result
first
due
logist
constraint
two
differ
nucleic
acid
extract
procedur
use
assess
valid
panel
due
differ
extract
volum
use
recoveri
effici
method
concentr
primari
specimen
eluent
quit
differ
may
account
differ
pathogen
detect
howev
note
previou
evalu
extract
method
found
perform
compar
yang
et
al
import
limit
evalu
conduct
differ
laboratori
frozen
sampl
ship
test
locat
result
evalu
key
knowledg
gap
ftd
tac
respiratori
platform
address
demonstr
platform
could
reliabl
detect
clinic
relev
concentr
bacteri
viral
pathogen
spike
nasal
wash
buffer
well
individu
pathogen
present
mix
sampl
interassay
agreement
vari
significantli
differ
nucleic
acid
extract
method
use
comparison
clinic
specimen
evalu
nucleic
acid
extract
held
constant
importantli
headtohead
evalu
describ
provid
direct
comparison
two
platform
unavail
elsewher
confirm
either
platform
would
appropri
detect
import
pathogen
respiratori
specimen
sinc
time
evalu
platform
adapt
includ
addit
pathogen
target
adopt
use
multicent
field
base
etiolog
studi
among
infant
children
tac
platform
oper
advantag
individu
reaction
updat
without
optim
multiplex
panel
low
sampl
volum
requir
minim
pipet
step
involv
advantag
ftd
platform
abil
use
less
special
wide
avail
realtim
pcr
equip
